DMAC Stock Analysis: Buy, Sell, or Hold?
DMAC - DiaMedica Therapeutics Inc. Common Stock
$7.62
0.18 (2.42%)
▲
5d:
+23.9%
30d:
+32.06%
90d:
+18.69%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When DMAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: DMAC is 13.9% above its trading range ($6.69). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: DMAC is 13.9% above its trading range ($6.69). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: DMAC is currently trading at $7.62, which is considered extended relative to its 30-day fair value range of $5.46 to $6.69.
Technical Outlook: Technically, DMAC is in a strong downtrend. The price is approaching resistance at $6.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+103.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DMAC is in a strong downtrend. The price is approaching resistance at $6.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+103.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.46 -
$6.69
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.9%
All Signals
- BEARISH: Price significantly overextended (+13.9% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 103.4% below Wall St target ($15.50)
Trading Range Analysis
30-Day Trading Range
$5.46 -
$6.69
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.74
(9.7%)
Support & Resistance Levels
Support Level
$5.30
Resistance Level
$6.45
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.66
Wall Street Target
$15.50
(+103.4%)
Share & Embed Analysis
Last updated: July 05, 2026 12:47 AM ET
Data refreshes hourly during market hours. Next update: 1:47 AM
Data refreshes hourly during market hours. Next update: 1:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DMAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
